[signal.]portfolio & asset diligence

Org: Demo Translational Institute — structured asset diligence, not investment advice.

← Portfolio

MECP2 Dosage-Controlled Gene Therapy

Edit / manage →

Rett syndrome

DiscoveryActiveGene therapy (AAV)NeurodevelopmentalInsufficient· low conf2 evidence-linked claims

Overview

Disease area
Neurodevelopmental
Indication
Rett syndromeMONDO:0010726
Mechanism of action
Dosage-sensitive MECP2 re-expression with feedback control
Development stage
Discovery
Institution
Riverside Children's Research Center
Principal investigators
L. Brandt, E. Okafor
Targets
MECP2
Pathways
Chromatin regulation
Trial registry
—

Intake & funding

Applications
  • L. Brandtunder_reviewUSD400,0002025-04-10
    Seed grant
Funding events

None recorded.

Scientific assessment

1 claims
  • Mechanistic RationaleStrong

    MECP2 is exquisitely dosage-sensitive (duplication syndrome mirrors loss); a feedback-controlled construct is required to avoid overexpression.

    datasetMONDO:0010726

Translational assessment

0 claims

No evidence linked yet.

Regulatory assessment

0 claims

No evidence linked yet.

Commercial assessment

0 claims

No evidence linked yet.

Execution assessment

1 claims
  • MilestonesContext

    Discovery-stage; key milestone is demonstrating dosage control in vivo before IND-enabling studies.

    internalplan-2025

Structured reviews

1 reviews
Insufficient· low confInternalDiscovery review2025-05-15
Strengths

Compelling dosage-control concept for a high unmet need.

Weaknesses

Discovery stage; dosage control not yet shown in vivo.

Improvement areas

Generate proof-of-concept for the feedback construct.

Internal rubric input (reviewer scoring — not a success probability)
Scientific validity
Translational readiness
Regulatory pathway
Commercial potential
Execution strength

Outcome

  • Active
    Discovery stage; dosage-control proof-of-concept in progress.2025-05-15

AI brief

flag off · defaultPhase 7

Runtime AI features are flag-gated and disabled by default. Set SIGNAL_LLM_ENABLED=1 (plus a provider key) to enable a grounded, source-cited brief generated from this asset's structured records — with forbidden-phrase and grounding validators enforcing no probability-of-success or buy/sell language.

Evidence tiers and reviewer rubric scores are internal, qualitative inputs — [signal.] surfaces never show a numeric probability of success or buy/sell language.